FHCHC along with the Yale School of Medicine has received a grant and begun recruiting patients to participate in a medical research study comparing different diabetes treatments. Last year, FHCHC's Diabetes Prevention Program (DPP), led by national principal co-investigator endocrinologist Dr. Anne Camp, along with Yale, participated in a competitive grant application and was one of more than 40 sites in the whole country awarded the National Institute of Health (NIH) grant to conduct the GRADE (Glycemia Reduction Approaches in Diabetes: A Comparative Effectiveness) Study. This is an exciting study because it is not related to drug experimentation, but rather looking to see what the most effective combination of treatments for patients with diabetes is.  

The goal is to find out which diabetes medicines work best for people who are over age 30, have type 2 diabetes diagnosed within the last ten years and are treated with Metformin--the first line gold standard diabetes treatment. The study will compare four medications that providers at FHCHC are already providing plus Metformin. Participants were recruited over a period of three years. These patients receive their diabetes medication for free during the duration of the study (through 2021).

It is an honor for FHCHC's DPP to be working with Yale School of Medicine and the NIH on this study and to be able to offer these already wonderfully proven, safe, and effective drugs for the next eight years.  

For more information, please contact Magalys Perez, RN, BSN at (203) 752-5268 or at

To see information regarding this study from the NIH, please click here.